Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats.
This study was designed to assess a local drug delivery system of an anticancer agent, doxorubicin (DOX), using fibrin glue (Beriplast P) as a drug carrier. In vitro release of DOX from the fibrin glue was examined by a dialysis method in the presence and absence of sodium alginate. The in vitro mean dissolution times of DOX with solution, fibrin glue, and fibrin glue containing sodium alginate were 3.7 h, 8.7 h, and 81 h, respectively, indicating a sustained release of DOX from fibrin glue, especially in the presence of sodium alginate. Fibrin glue containing 6 mg of DOX and 2.5 mg of sodium alginate was applied on the surface of an AH60C tumor at the back of rats. DOX concentrations in the tumor extracellular fluid were monitored by a microdialysis method. Local application of DOX using fibrin glue containing sodium alginate to the tumor resulted in extremely higher concentrations in the tumor extracellular fluid than those in plasma (AUC ratio > 800), indicating an advantage of the site-specific delivery of DOX using fibrin glue with sodium alginate. The tumor volumes were inversely correlated with tumor extracellular fluid-to-plasma AUC ratios (r = 0.882), suggesting the relevance of tumor size in the drug efflux from tumor to blood. In conclusion, the site-specific delivery of DOX using fibrin glue with sodium alginate to the tumor was demonstrated to be advantageous with regard to the extent and duration of drug concentrations in the tumor extracellular fluid, as assessed by a microdialysis technique.
Kitazawa
H
H
Department of Hospital Pharmacy, Toyama Medical and Pharmaceutical University, Japan.
Sato
H
H
Adachi
I
I
Masuko
Y
Y
Horikoshi
I
I
D000464:Alginates; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004337:Drug Carriers; D005110:Extracellular Space / Q000378:metabolism; D015718:Fibrin Tissue Adhesive; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D009368:Neoplasm Transplantation; D051381:Rats
D000464:Alginates; D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D015718:Fibrin Tissue Adhesive; D006603:Hexuronic Acids; D004317:Doxorubicin; D020723:Glucuronic Acid